Prostate adenocarcinoma grade group 1: Rationale for retaining a cancer label in the 2022 World Health Organization Classification Editorial

  

Authors:	Netto, G. J.; Amin, M. B.; Compérat, E. M.; Gill, A. J.; Hartmann, A.; Moch, H.; Menon, S.; Raspollini, M. R.; Rubin, M. A.; Srigley, J. R.; Hoon Tan, P.; Tickoo, S. K.; Tsuzuki, T.; Turajlic, S.; Cree, I.; Berney, D. M.
Title:	Prostate adenocarcinoma grade group 1: Rationale for retaining a cancer label in the 2022 World Health Organization Classification
Keywords:	cancer grading; adenocarcinoma; prostate specific antigen; evidence based practice; editorial; pathology; gleason score; prostate-specific antigen; prostatic neoplasms; prostate; active surveillance; prostate tumor; patient compliance; world health organization; prostate adenocarcinoma; cancer classification; seminal vesicle; cost benefit analysis; preventive health service; neoplasm grading; humans; human; male; malignant neoplasm
Journal Title:	European Urology
Volume:	83
Issue:	4
ISSN:	0302-2838
Publisher:	Elsevier Science, Inc.
Date Published:	2023-04-01
Start Page:	301
End Page:	303
Language:	English
DOI:	10.1016/j.eururo.2022.09.015
PUBMED:	36202687
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85139188504&doi=10.1016%2fj.eururo.2022.09.015&partnerID=40&md5=1bc8d3eef583338c2efcd4ee8b1f99d0
Notes:	Editorial -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/204487